ProBility Media (PBYA) 10-K 15 Jun 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	31-May-14	Jun. 10, 2015	Nov. 30, 2013
Document And Entity Information [Abstract]
Entity Registrant Name	PANTHER BIOTECHNOLOGY, INC.
Entity Central Index Key	1530981
Trading Symbol	pbya
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	-26
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		4,662,500
Entity Public Float			$0
Document Type	10-K
Document Period End Date	31-May-14
Amendment Flag	FALSE
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	31-May-14	31-May-13
Current Assets
Cash	$70,269	$12,331
Accounts receivable, net of allowance of $11,428 and $5,000, respectively	18,105	8,730
Prepaid expenses	7,988	326
Total current assets	96,362	21,387
Long-Term Assets
Property, plant and equipment, net of accumulated depreciation of $3,567 and $1,197, respectively	8,971	3,290
License deposit	24,000
Total Assets	129,333	24,677
Current Liabilities
Accounts payable and accrued liabilities	52,595	2,459
Deferred revenue	11,359
Related party advances	25,000
Total liabilities	88,954	2,459
Commitments and Contingencies
Stockholders' Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized; 4,662,500 and 3,637,500 shares issued and outstanding, respectively	4,663	3,638
Additional paid-in capital	49,587	30,112
Accumulated deficit	-13,871	-11,532
Total stockholders' equity	40,379	22,218
Total Liabilities and Stockholders' Equity	$129,333	$24,677

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	31-May-14	31-May-13
Statement of Financial Position [Abstract]
Allowance for accounts receivable (in dollars)	$11,428	$5,000
Accumulated depreciation of property, plant and equipment (in dollars)	$3,567	$1,197
Preferred stock, par value (in dollar per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollar per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	4,662,500	3,637,500
Common stock, shares outstanding	4,662,500	3,637,500

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	31-May-14	31-May-13
Income Statement [Abstract]
Revenue	$256,855	$73,496
Cost of revenue	55,031	13,177
Gross profit	201,824	60,319
Operating expenses:
Selling, general and administrative	203,163	67,111
Total operating expenses	203,163	67,111
Operating loss	-1,339	-6,792
Other expense:
Loss on impairment of asset deposit	-1,000
Net loss	($2,339)	($6,792)
Net loss per common share, basic and diluted (in dollars per share)	$0	$0
Weighted average number of common shares outstanding, basic and diluted (in shares)	4,468,733	3,046,507

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at May. 31, 2012	$2,600	$10,400	($4,740)	$8,260
Balance (in shares) at May. 31, 2012	2,600,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued for cash	1,038	19,712		20,750
Common shares issued for cash (in shares)	1,037,500
Net loss			-6,792	-6,792
Balance at May. 31, 2013	3,638	30,112	-11,532	22,218
Balance (in shares) at May. 31, 2013	3,637,500			3,637,500
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued for cash	1,025	19,475		20,500
Common shares issued for cash (in shares)	1,025,000
Net loss			-2,339	-2,339
Balance at May. 31, 2014	$4,663	$49,587	($13,871)	$40,379
Balance (in shares) at May. 31, 2014	4,662,500			4,662,500

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	31-May-14	31-May-13
Cash Flows from Operating Activities:
Net loss	($2,339)	($6,792)
Adjustments to reconcile net loss to net cash provided by / (used in) operations:
Bad debt expense	14,850	5,000
Depreciation and amortization	5,920	859
Impairment of asset deposit	1,000
Changes in assets and liabilities:
Accounts receivable	-24,225	-8,382
Prepaid expenses	-11,212	1,688
Accounts payable and accrued expenses	50,136	2,336
Deferred revenue	11,359	-625
Net cash proved by /(used in) operating activities	45,489	-5,916
Cash Flows from Investing Activities:
Purchase of property and equipment	-8,051	-3,272
License deposit	-25,000
Net cash used in investing activities	-33,051	-3,272
Cash Flows from Financing Activities:
Proceeds from related party advances	25,000
Proceeds from issuance of common stock	20,500	20,750
Net cash provided by financing activities	45,500	20,750
Net increase in cash	57,938	11,562
Cash at beginning of year	12,331	769
Cash at end of year	70,269	12,331
Supplemental Cash Flow Disclosure:
Interest paid
Taxes paid

ORGANIZATION_AND_DESCRIPTION_O

ORGANIZATION AND DESCRIPTION OF BUSINESS	12 Months Ended
	31-May-14
Organization And Description Of Business [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS
	Organization and Business Activity
	Panther Biotechnology, Inc. (the "Company") was incorporated in the State of Nevada on July 11, 2011.  The Company was originally incorporated as New Era Filing Services Inc., changed its name to NEF Enterprises, Inc. on October 4, 2011 and then changed its name to Panther Biotechnology, Inc. on May 29, 2014.  The Company incorporated a wholly-owned subsidiary, PubCo Reporting Services, Inc., formerly known as New Era Filing Services, Inc., in Florida on November 20, 2012.
	The Company is an early stage company that offers Securities Exchange Commission ("SEC") compliance filing services, through its wholly-owned subsidiary.  Our clients are companies and individuals with SEC reporting requirements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	31-May-14
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Consolidation
	The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, PubCo Reporting Services, Inc. All significant intercompany balances and transactions have been eliminated in these consolidated financial statements.
	Basis of Presentation
	The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America ("GAAP").  These consolidated financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.
	Use of estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period.  Actual results could differ from those estimates. The Company's periodic filings with the Securities and Exchange Commission include, where applicable, disclosures of estimates, assumptions, uncertainties and markets that could affect the financial statements and future operations of the Company.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with original maturities of less than three months, which are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss in value, to be cash equivalents.
	Concentrations of Credit Risks
	The Company's financial instruments that are exposed to concentrations of credit risk primarily consist of its cash and cash equivalents.  The Company places its cash and cash equivalents with financial institutions of high credit worthiness.  At times, its cash and cash equivalents with a particular financial institution may exceed any applicable government insurance limits.  The Company's management plans to assess the financial strength and credit worthiness of any parties to which it extends funds, and as such, it believes that any associated credit risk exposures are limited.
	Accounts Receivable
	Accounts receivable consist of charges for service provided to customers. An allowance for doubtful accounts is considered to be established for any amounts that may not be recoverable, which is based on an analysis of the Company's customer credit worthiness, and current economic trends.  Based on management's review of accounts receivable, an $11,528 and $5,000 allowance for doubtful accounts was recorded at May 31, 2014 and 2013, respectively.   Receivables are determined to be past due, based on payment terms of original invoices.  The Company does not typically charge interest on past due receivables. During the year ended May 31, 2014, the Company determined that $8,322 of accounts receivable were not collectible and recorded a direct write-off of the amount.
	Deposits and Prepaid Expenses
	Deposits represent advance payments made for the acquisition of assets.  Prepaid expenses include annual software costs that are paid up-front to the software licensor and are amortized over a twelve-month period.  Amortization expense of $3,550 and $0 was recognized in the years ended May 31, 2014 and 2013, respectively, related to prepaid software costs. The Company recognized $1,000 and $0 in impairment of deposits in the years ended May 31, 2014 and 2013, respectively, related to the expiration of option terms for a license agreement.
	Impairment of Long-Lived Assets
	The Company reviews the carrying value of its long-lived assets annually or whenever events or changes in circumstances indicate that the historical cost-carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of the asset by estimating the future net undiscounted cash flows expected to result from the asset, including eventual disposition. If the future net undiscounted cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset's carrying value and estimated fair value.
	Property, Plant and Equipment
	Computer equipment is stated at cost, net of accumulated depreciation. Depreciation on computer equipment is computed using the straight-line method over the estimated useful lives of the equipment, generally three years. Depreciation begins in the month of acquisition.
	Revenue Recognition
	The Company recognizes revenue from the sale of services in accordance with ASC 605, "Revenue Recognition."  Revenue consists of SEC compliance services; focusing on corporate and individual reporting requirements. Sales income is recognized only when all of the following criteria have been met:
		i)	Persuasive evidence for an agreement exists;
		ii)	Service has been provided;
		iii)	The fee is fixed or determinable; and
		iv)	Collection is reasonably assured.
	It is common to have services paid in advance, in such cases, the Company defers revenue recognition until services have been performed.   As of May 31, 2014 and 2013, we recorded deferred revenue of $11,359 and $0 respectively.
	Advertising
	The costs of advertising are expensed as incurred.  Advertising expense was $14,733 and $3,690 for the years ended May 31, 2014 and 2013, respectively.
	Income Taxes
	Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax basis of assets and liabilities and the tax rates in effect when these differences are expected to reverse.  Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
	Loss per Share
	Basic loss per common share equals net loss divided by weighted average common shares outstanding during the period. Diluted loss per share includes the impact on dilution from all contingently issuable shares, including options, warrants and convertible securities. The common stock equivalents from contingent shares are determined by the treasury stock method. The Company incurred net losses for the years ended May 31, 2014 and 2013, and therefore, basic and diluted loss per share for those periods are the same as all potential common equivalent shares would be antidilutive.
	The Company has no potentially dilutive securities, such as options or warrants, currently issued and outstanding.
	Recent Accounting Pronouncements
	Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Company's management believes that these recent pronouncements will not have a material effect on the Company's consolidated financial statements.
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and has not yet determined the method by which the Company will adopt the standard in 2017.
	Subsequent Events
	The Company has evaluated all transactions through the date the consolidated financial statements were issued for subsequent event disclosure consideration.
	In June 2014, the Financial Accounting Standards Board ("FASB") issued ASU 2014-10 "Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation". ASU 2014-10 eliminates all incremental financial reporting requirements for development stage entities by removing ASC Topic 915 "Development Stage Entities", from the FASB Accounting Standards Codification. The ASU 2014-10 clarified that the guidance in Topic 275 "Risks and Uncertainties" is applicable to entities that have not yet commenced operations. Accordingly, upon adopting the ASU 2014-10 and eliminating development stage information, entities should re-evaluate their disclosures under Topic 275. The Company decided to early adopt this pronouncement in the second quarter of 2014. As a result, cumulative information in the Company's statements of operations, its statements of cash flows and the notes to its unaudited consolidated financial statements was removed.
	In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. The new standard requires management to assess the company's ability to continue as a going concern. Disclosures are required if there is substantial doubt as to the company's continuation as a going concern within one year after the issue date of financial statements. The standard provides guidance for making the assessment, including consideration of management's plans which may alleviate doubt regarding the company's ability to continue as a going concern. ASU 2014-15 is effective for years beginning after December 15, 2016. We do not expect the adoption of this pronouncement to have a material impact on our consolidated financial statements.

GOING_CONCERN_AND_LIQUIDITY_CO

GOING CONCERN AND LIQUIDITY CONSIDERATIONS	12 Months Ended
	31-May-14
Going Concern And Liquidity Considerations [Abstract]
GOING CONCERN AND LIQUIDITY CONSIDERATIONS	NOTE 3 - GOING CONCERN AND LIQUIDITY CONSIDERATIONS
	The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.  The Company has a cumulative net loss since inception from operations of $13,871 and has required additional capital raises and advances from shareholders' to support its operations.  These factors raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time.  The Company's continuation as a going concern is dependent upon its ability to generate revenues and its ability to continue receiving capital from third parties.  No assurance can be given that the Company will be successful in these efforts.
	The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	31-May-14
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 4 – PROPERTY, PLANT AND EQUIPMENT
	Property, plant and equipment assets consist of the following:
		31-May-14			31-May-13
	Computer equipment and furniture	$	12,538		$	4,487
	Less: accumulated depreciation		(3,567	)		(1,197	)
	Computer equipment, net	$	8,971		$	3,290
	Depreciation expense was $2,370 and $859 for the years ended May 31, 2014 and 2013, respectively.

RELATED_PARTY_ADVANCES

RELATED PARTY ADVANCES	12 Months Ended
	31-May-14
Related Party Transactions [Abstract]
RELATED PARTY ADVANCES	NOTE 5 – RELATED PARTY ADVANCES
	During the year ended May 31, 2014, certain officers, directors and shareholders of the Company advanced $25,000 to the Company which was paid to Northwestern University as a deposit for the acquisition of a license.  The license agreement contained an option exercisable by the Company to acquire a license related to certain patents held by Northwestern University.   The option payment was $1,000 and had a term of six months and the remaining $24,000 was an additional deposit to be applied to the final purchase price at closing.  The Company and Northwestern University were unable to come to terms for acquisition before the option expired.  Accordingly, the Company recorded an impairment of the option value of $1,000.  The Company and Northwestern University closed on the license agreement in January 2015.  See Note 8.  The related parties advances have no conversion provisions into equity, are due on demand and do not incur interest.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	31-May-14
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 6 - INCOME TAXES
	Each of the three tax years the Company has been in operation are subject to examination by the Internal Revenue Service.  The Company has net operating losses that begin to expire on May 31, 2031.
	The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 34% to the net income/(loss) before provision for income taxes for the following reasons:
		31-May-14			31-May-13
	Income tax benefit at statutory rate	$	(795	)	$	(2,309	)
	Meals and entertainment		116			-
	Temporary differences		(5,739	)		-
	Change in valuation allowance		6,418			2,309
	Income tax expense per books	$	-		$	-	)
	Net deferred tax liabilities consist of the following components as of:
		31-May-14			31-May-13
	NOL carryover	$	10,339		$	3,921
	Valuation allowance		(10,339	)		(3,921	)
	Net deferred tax liability	$	-		$	-

SHAREHOLDERS_EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	31-May-14
Stockholders' Equity Note [Abstract]
SHAREHOLDER'S EQUITY	NOTE 7 – SHAREHOLDERS' EQUITY
	Authorized Stock
	The Company has authorized 100,000,000 common shares and 10,000,000 preferred shares, both with a par value of $0.001 per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.
	Common Share Issuances
	During the years ended May 31, 2014 and 2013, the Company issued a total of 2,062,500 common shares for $41,250 in cash as follows:
		·	During August 2013, the Company issued to unaffiliated investors 1,025,000 shares of common stock at $0.02 per share for $20,500 in net cash proceeds.
		·	During November 2012 to January 2013, the Company issued to unaffiliated investors 1,037,500 shares of common stock at $0.02 per share for $20,750 in net cash proceeds.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	31-May-14
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS
	License Agreement with Northwestern University
	On January 26, 2015, the Company entered a license agreement with Northwestern University ("Northwestern"). Northwestern is the owner of certain patents and grants for cancer treatments of which the Company has obtained an exclusive license under a Patent Rights agreement and a non-exclusive license under a Know-How agreement (together the "Licensed Product").
	According to the agreement, the Company must reach the following milestones to maintain the licenses:
		a)	Raise funds of at least $3 million within the first 12 months of the closing date;
		b)	Initiate Good Laboratory Practices in preclinical studies with a Licensed Product within 18 months of the closing date;
		c)	File an Investigational New Drug application within 4 years of the closing date;
		d)	First dosing of a patient in a Phase I clinical trial for a Licensed Product within 5 years of the closing date;
		e)	First dosing of a patient in a Phase II clinical trial for a Licensed Product within 6 years of the closing date;
		f)	First dosing of a patient in a Phase III clinical trial for a Licensed Product within eight years of the closing date;
		g)	Submit a New Drug Application for a Licensed Product within 10 years of the closing date;
		h)	Complete and submit to Northwestern a business plan for commercialization of a Licensed Product within 1 year of submission of a New Drug Application ("NDA") for such Licensed Product.
	In consideration of the license granted by Northwestern, the Company shall pay to Northwestern the following:
		a)	A non-creditable, non-refundable licensing fee of $24,000 within 30 days of the closing date (which was previously paid);
		b)	The Company will issue to Northwestern a number of shares of its common stock that will represent 2% of the total outstanding shares of the Company and, in consideration of her role as co-founder and in anticipation of entering into a research agreement with Northwestern to support research in her laboratory, the Company will issue to Dr. Sui Huang a number of shares of common stock that will represent 2% of the total outstanding shares of the Company;
		c)	The Company shall pay to Northwestern a non-creditable, non-refundable annual maintenance fee on each anniversary of the closing date according to the following schedule until the Company receives regulatory approval from the Federal Drug Administration (or foreign equivalent) ("Regulatory Approval") of the first Licensed Product(s):
	Time Periods	Amount
	1st anniversary	0
	2nd-4th anniversaries	$7,000
	5th and 6th anniversaries	$25,000
	7th anniversary and each year thereafter	$50,000
	In the first full calendar year following Regulatory Approval, Northwestern shall credit 1/12 of the annual maintenance fee paid by the Company against the minimal royalty payments (see item (e) below) due for each full month remaining between January 1 of that year and the anniversary of the closing date.
		d)	The following non-creditable and non-refundable milestone payments upon the achievement of particular milestones in the development of Licensed Products (none of which have occurred):
		-1	$25,000 upon filing of Investigational New Drug application for a Licensed Product
		-2	$50,000 upon dosing first patient in Phase I trial (or foreign equivalent) for a Licensed Product
		-3	$100,000 upon dosing first patient in Phase II trial (or foreign equivalent) for a Licensed Product
		-4	$250,000 upon dosing first patient in Phase III trial (or foreign equivalent) for a Licensed Product
		-5	$1,500,000 upon Regulatory Approval of a Licensed Product
		e)	Beginning the first full calendar year after Regulatory Approval of a Licensed Product in the United States, Canada, Japan, France, Germany, United Kingdom, Australia, or Italy, or the year 2025, whichever comes first, the Company shall pay to Northwestern minimum royalty payments of $200,000 per year, on a quarterly basis.
		f)	The Company will reimburse Northwestern's out of pocket patent expenses totaling approximately $25,000 as of November 18, 2014. All future patent costs for the preparation, filing, prosecution, and maintenance of the Patent Rights, shall be borne by the Company. Payment will be deferred until the earlier of a) the date the Company closes on its first round of financing after the closing date or b) 1 year from the closing date;
		g)	A running royalty of (a) 5% of net sales of Licensed Products if such Licensed Product is covered by Patent Rights in the country where such Licensed Product is manufactured or sold and (b) 2% of net sales of Licensed Products in all other countries. In the event that Licensee enters into other license agreements) with third parties with respect to intellectual property which in the Company's opinion is legally required for the manufacture, use or sale of Licensed Product(s), the Company may offset amounts paid to such third parties against earned royalties due Northwestern hereunder, by reducing Licensee's obligation to Northwestern by 0.25% for each 1% of royalty rate payable to third parties; provided, however, that in no event will the royalty rate otherwise due to Northwestern be less than 2.5%;
		h)	In addition to the running royalties described above, 15% of any payments, including, but not limited to, sublicense issue fees or milestones received from sub licensees as consideration for Patent Rights or Licensed Products prior to filing of an NDA; 5% after filing an NDA;
		i)	In the event of a corporate partnership for the development and/or commercialization of a Licensed Product, 10% of any payments received from such corporate partner as consideration for Patent Rights or Licensed Products. Payments received by the Company for equity and payments allocated solely for research are excluded;
		j)	The Company subject to certain payments if the Company issues sublicenses, permit assignments on the agreement, or in the event of a corporate partnership for the development and /or commercialization of a licensed product.
		k)	In the event of a permitted assignment of the agreement, 10% of any payments received from such assignee as consideration for Patent Rights or Licensed Products.
	The agreement will continue in effect, on a country-by country basis, until the expiration of the last to expire of Patent Rights.
	License Agreement with University of Rochester
	On April 16, 2015, the Company entered into an exclusive patent license agreement with University of Rochester ("Rochester") effective as of the 31st day of March, 2015. Rochester grants to the Company a worldwide exclusive, royalty-bearing license, with the right to sublicense, for patents and technology related to the treatment of diabetes (the "Patent Products"). According to the agreement, the Company will reimburse Rochester for all mutually agreed fees and costs relating to the filing, prosecution, and maintenance of patent applications, including without limitation, interferences, oppositions, and reexaminations, and the maintenance and defense of patents in patent rights, including fees and cost incurred on, and after the closing date of the agreement.
	As partial consideration for the rights conveyed by Rochester under this agreement, the Company agreed to issue 32,310 shares of the Company's common stock to Rochester as a one-time, non-refundable, non-creditable license issue fee valued at $200,000 based upon the average price per share in the week preceding the closing date. The transaction was completed on April 30, 2015. Rochester may not transfer the shares before August 30, 2016.
	In addition to the above license fee, for the term of the agreement on an annual basis measured from the closing date of the agreement, the Company will pay at the beginning of the year a non-refundable minimum annual maintenance fee of $15,000 in cash or Company stock each year prior to the onset of clinical trials. Rochester will waive the pre-clinical trial annual maintenance fee if the Company spends at least $200,000 annually on the drug development that would impinge the patent rights conveyed.  After onset of clinical trials, the Company will pay a non-refundable minimum annual maintenance fee of $25,000 in cash or Company stock each year or part of year until the first product is commercialized and sales royalty payments begin. Annual maintenance fees paid in cash will be credited against the costs of maintaining the Patent Rights for that year.
	During the term of this Agreement, the Company agrees to pay to Rochester an earned royalty of 5% of the first $10,000,000, 4% of the second $10,000,000, 3% of the third $10,000,000, 2% of the fourth $10,000,000 in net sales revenue produced from Patent Products, and l % of all remaining net sales revenue produced from Patent Products. Earned royalty payments are due and payable within 30 days of the end of each calendar quarter.
	The Company agrees to pay to Rochester 50% of all cash and non-cash consideration derived from sublicenses granted by the Company in Patent Products, excluding earned royalties, loans, equity investments, and research and development support.
	The Company agrees to pay Rochester the milestone payments per product as set forth below:
		a)	If the Company sponsors Phase I, II and III clinical trials, the Company will pay $500,000 within 30 days of approval of any Patent Product;
		b)	If the Company sells a controlling interest in or sublicenses substantially all of the Patent Products before the initiation of Phase II clinical trial, the Company will pay:
		1)	$200,000 within 30 days of initiation of Phase II clinical trial;
		2)	$200,000 within 30 days of initiation of Phase III clinical trial; and
		3)	$300,000 within 30 days of approval of a Patent Product
	The term of this Agreement will commence on the closing date and will end upon the latest of (i) expiration of the last-to-expire valid claim of the Patent Products; and (ii) the 10 year anniversary of commercial launch of any Patent Product.
	Asset Purchase Agreement
	On April 6, 2015, the Company entered into an asset acquisition agreement with Faulk Pharmaceuticals, Inc. ("Faulk"). The assets include 23 granted patents owned by Faulk, related to treatment of cancer, virus infections, and treatment of parasitic infections.
	The Company agreed to issue 50,000 shares of common stock of the Company at the closing, which is anticipated to be in June 2015.   The shares may be sold by Faulk, assigned or transfer in the open market subject to compliance with securities laws and the following schedule:
		1)	33% of the shares beginning 6 months after the closing date
		2)	an additional 33% of the shares beginning 9 months after the closing date
		3)	the remaining 34% of the shares beginning 12 months after the closing date
	For each calendar year continuing until the date that is 10 years after the expiration of the last of the patents conveyed to the Company, a royalty on net revenue received by the Company in that year from the sales or licenses of any products commercialized by the Company, its successors or assignees as a direct result of the assets acquired or the technology or processes related to the assets acquired, in the following amount:
		1)	5% of the first $10,000,000 in such net revenue;
		2)	4% of the second $10,000,000 in such net revenue
		3)	3% of the third $10,000,000 in such net revenue
		4)	2% of the forth $10,000,000 in such net revenue and
		5)	1 % of such net revenue in excess of $40,000,000
	Capital stock issuances
	On February 4, 2015, the Board of Directors approved the issuance of 1,345,000 shares of restricted common stock to the directors for their service. The shares will be earned as follows:
		1)	33% of the restriction will be removed on February 4, 2016,
	2)	an additional 33% of the restriction will be removed on February 4, 2017,
	3)	and the final 34% of the restriction will be removed on February 4, 2018.
The closing price on February 4, 2015 was $2.60, the date of the grant.  As of the date of this filing, the shares have not been issued.
On April 2, 2015, the Board of Directors approved the issuance of 50,000 (as described above) shares to purchase the assets of Faulk. The shares will be valued on the date of closing of the purchase of the assets.  As of the date of this filing, the shares have not been issued.
On April 2, 2015, the Board of Directors approved the issuance of 260,000 shares of restricted common stock to two directors and officers of the Company for services. The shares will be earned as follows:
	1)	33% of the restriction will be removed on April 2, 2016,
	2)	an additional 33% of the restriction will be removed on April 2, 2017,
	3)	and the final 34% of the restriction will be removed on April 2, 2018.
The closing share price on April 2, 2015 was $6.95, the date of the grant.  As of the date of this filing, the shares have not been issued.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	31-May-14
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation
	The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, PubCo Reporting Services, Inc. All significant intercompany balances and transactions have been eliminated in these consolidated financial statements.
Basis of Presentation	Basis of Presentation
	The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America ("GAAP").  These consolidated financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.
Use of estimates	Use of estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period.  Actual results could differ from those estimates. The Company's periodic filings with the Securities and Exchange Commission include, where applicable, disclosures of estimates, assumptions, uncertainties and markets that could affect the financial statements and future operations of the Company.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid investments with original maturities of less than three months, which are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss in value, to be cash equivalents.
Concentrations of Credit Risks	Concentrations of Credit Risks
	The Company's financial instruments that are exposed to concentrations of credit risk primarily consist of its cash and cash equivalents.  The Company places its cash and cash equivalents with financial institutions of high credit worthiness.  At times, its cash and cash equivalents with a particular financial institution may exceed any applicable government insurance limits.  The Company's management plans to assess the financial strength and credit worthiness of any parties to which it extends funds, and as such, it believes that any associated credit risk exposures are limited.
Accounts Receivable	Accounts Receivable
	Accounts receivable consist of charges for service provided to customers. An allowance for doubtful accounts is considered to be established for any amounts that may not be recoverable, which is based on an analysis of the Company's customer credit worthiness, and current economic trends.  Based on management's review of accounts receivable, an $11,528 and $5,000 allowance for doubtful accounts was recorded at May 31, 2014 and 2013, respectively.   Receivables are determined to be past due, based on payment terms of original invoices.  The Company does not typically charge interest on past due receivables. During the year ended May 31, 2014, the Company determined that $8,322 of accounts receivable were not collectible and recorded a direct write-off of the amount.
Deposits and Prepaid Expenses	Deposits and Prepaid Expenses
	Deposits represent advance payments made for the acquisition of assets. Prepaid expenses include annual software costs that are paid up-front to the software licensor and are amortized over a twelve-month period. Amortization expense of $3,550 and $0 was recognized in the years ended May 31, 2014 and 2013, respectively, related to prepaid software costs. The Company recognized $1,000 and $0 in impairment of deposits in the years ended May 31, 2014 and 2013, respectively, related to the expiration of option terms for a license agreement.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	The Company reviews the carrying value of its long-lived assets annually or whenever events or changes in circumstances indicate that the historical cost-carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of the asset by estimating the future net undiscounted cash flows expected to result from the asset, including eventual disposition. If the future net undiscounted cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset's carrying value and estimated fair value.
Property, Plant and Equipment	Property, Plant and Equipment
	Computer equipment is stated at cost, net of accumulated depreciation. Depreciation on computer equipment is computed using the straight-line method over the estimated useful lives of the equipment, generally three years. Depreciation begins in the month of acquisition.
Revenue Recognition	Revenue Recognition
	The Company recognizes revenue from the sale of services in accordance with ASC 605, "Revenue Recognition."  Revenue consists of SEC compliance services; focusing on corporate and individual reporting requirements. Sales income is recognized only when all of the following criteria have been met:
		i)	Persuasive evidence for an agreement exists;
		ii)	Service has been provided;
		iii)	The fee is fixed or determinable; and
		iv)	Collection is reasonably assured.
	It is common to have services paid in advance, in such cases, the Company defers revenue recognition until services have been performed.   As of May 31, 2014 and 2013, we recorded deferred revenue of $11,359 and $0 respectively.
Advertising	Advertising
	The costs of advertising are expensed as incurred.  Advertising expense was $14,733 and $3,690 for the years ended May 31, 2014 and 2013, respectively.
Income Taxes	Income Taxes
	Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax basis of assets and liabilities and the tax rates in effect when these differences are expected to reverse.  Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
Loss per Share	Loss per Share
	Basic loss per common share equals net loss divided by weighted average common shares outstanding during the period. Diluted loss per share includes the impact on dilution from all contingently issuable shares, including options, warrants and convertible securities. The common stock equivalents from contingent shares are determined by the treasury stock method. The Company incurred net losses for the years ended May 31, 2014 and 2013, and therefore, basic and diluted loss per share for those periods are the same as all potential common equivalent shares would be antidilutive.
	The Company has no potentially dilutive securities, such as options or warrants, currently issued and outstanding.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Company's management believes that these recent pronouncements will not have a material effect on the Company's consolidated financial statements.
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and has not yet determined the method by which the Company will adopt the standard in 2017.
Subsequent Events	Subsequent Events
	The Company has evaluated all transactions through the date the consolidated financial statements were issued for subsequent event disclosure consideration.
	In June 2014, the Financial Accounting Standards Board ("FASB") issued ASU 2014-10 "Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation". ASU 2014-10 eliminates all incremental financial reporting requirements for development stage entities by removing ASC Topic 915 "Development Stage Entities", from the FASB Accounting Standards Codification. The ASU 2014-10 clarified that the guidance in Topic 275 "Risks and Uncertainties" is applicable to entities that have not yet commenced operations. Accordingly, upon adopting the ASU 2014-10 and eliminating development stage information, entities should re-evaluate their disclosures under Topic 275. The Company decided to early adopt this pronouncement in the second quarter of 2014. As a result, cumulative information in the Company's statements of operations, its statements of cash flows and the notes to its unaudited consolidated financial statements was removed.
	In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. The new standard requires management to assess the company's ability to continue as a going concern. Disclosures are required if there is substantial doubt as to the company's continuation as a going concern within one year after the issue date of financial statements. The standard provides guidance for making the assessment, including consideration of management's plans which may alleviate doubt regarding the company's ability to continue as a going concern. ASU 2014-15 is effective for years beginning after December 15, 2016. We do not expect the adoption of this pronouncement to have a material impact on our consolidated financial statements.

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	31-May-14
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment		31-May-14			31-May-13
	Computer equipment and furniture	$	12,538		$	4,487
	Less: accumulated depreciation		(3,567	)		(1,197	)
	Computer equipment, net	$	8,971		$	3,290

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	31-May-14
Income Tax Disclosure [Abstract]
Schedule of provision for income taxes		31-May-14			31-May-13
	Income tax benefit at statutory rate	$	(795	)	$	(2,309	)
	Meals and entertainment		116			-
	Temporary differences		(5,739	)		-
	Change in valuation allowance		6,418			2,309
	Income tax expense per books	$	-		$	-	)
Schedule of net deferred tax liabilities		31-May-14			31-May-13
	NOL carryover	$	10,339		$	3,921
	Valuation allowance		(10,339	)		(3,921	)
	Net deferred tax liability	$	-		$	-

SUBSEQUENT_EVENTS_Tables

SUBSEQUENT EVENTS (Tables)	12 Months Ended
	31-May-14
Subsequent Events [Abstract]
Schedule of subsequent events	Time Periods	Amount
	1st anniversary	0
	2nd-4th anniversaries	$7,000
	5th and 6th anniversaries	$25,000
	7th anniversary and each year thereafter	$50,000

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals) (USD $)	12 Months Ended
	31-May-14	31-May-13
Accounting Policies [Abstract]
Allowance for doubtful accounts	$11,428	$5,000
Accounts receivable direct write-off	8,322
Amortization expense	3,550	0
Loss on impairment of asset deposit	1,000
Depreciation method	Straight-line method
Estimated useful lives of equipment	3 years
Deferred revenue	11,359
Advertising expense	$14,733	$3,690

GOING_CONCERN_AND_LIQUIDITY_CO1

GOING CONCERN AND LIQUIDITY CONSIDERATIONS (Detail Textuals) (USD $)	31-May-14	31-May-13
Going Concern And Liquidity Considerations [Abstract]
Cumulative net loss	($13,871)	($11,532)

PROPERTY_PLANT_AND_EQUIPMENT_D

PROPERTY, PLANT AND EQUIPMENT (Details) (USD $)	31-May-14	31-May-13
Property, Plant and Equipment [Abstract]
Computer equipment and furniture	$12,538	$4,487
Less: accumulated depreciation	-3,567	-1,197
Computer equipment, net	$8,971	$3,290

PROPERTY_PLANT_AND_EQUIPMENT_D1

PROPERTY, PLANT AND EQUIPMENT (Detail Textuals) (USD $)	12 Months Ended
	31-May-14	31-May-13
Property, Plant and Equipment [Abstract]
Depreciation expense	$2,370	$859

RELATED_PARTY_ADVANCES_Detail_

RELATED PARTY ADVANCES (Detail Textuals) (USD $)	12 Months Ended
	31-May-14
Related Party Transactions [Abstract]
Advanced from officers, directors and shareholders	$25,000
Payment to repurchase stock option	1,000
Remaining Additional Deposit	24,000
Loss on impairment of asset deposit	$1,000

INCOME_TAXES_Summary_of_provis

INCOME TAXES - Summary of provision for income taxes (Details) (USD $)	12 Months Ended
	31-May-14	31-May-13
Income Tax Disclosure [Abstract]
Income tax expense at statutory rate	($795)	($2,309)
Meals and entertainment	116
Temporary differences	-5,739
Change in valuation allowance	6,418	2,309
Income tax expense per books

INCOME_TAXES_Summary_of_deferr

INCOME TAXES - Summary of deferred tax liabilities (Details 1) (USD $)	31-May-14	31-May-13
Income Tax Disclosure [Abstract]
NOL carryover	$10,339	$3,921
Valuation allowance	-10,339	-3,921
Net deferred tax liability

INCOME_TAXES_Detail_Textuals

INCOME TAXES (Detail Textuals)	12 Months Ended
	31-May-14	31-May-13
Income Tax Disclosure [Abstract]
Statutory federal income tax rate	34.00%	34.00%

SHAREHOLDERS_EQUITY_Detail_Tex

SHAREHOLDERS' EQUITY (Detail Textuals) (USD $)	12 Months Ended		1 Months Ended	3 Months Ended
	31-May-14	31-May-13	31-May-13	Jan. 31, 2013
Class of Stock [Line Items]
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, par value (in dollar per share)	$0.00	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred stock, par value (in dollar per share)	$0.00	$0.00	$0.00
Number of votes entitled to each common shareholder	One vote
Common shares issued for cash, value	$20,500	$20,750
Unaffiliated Investors
Class of Stock [Line Items]
Common shares issued for cash (in shares)			1,025,000	1,037,500
Common stock issued per share (in dollars per share)			$0.02	$0.02
Common shares issued for cash, value			$20,500	$20,750

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (Subsequent Event, Northwestern University ("Northwestern"), License Agreement, USD $)	1 Months Ended
	Jan. 26, 2015
1st anniversary
Subsequent Event [Line Items]
Maintenance fee	$0
2nd-4th anniversaries
Subsequent Event [Line Items]
Maintenance fee	7,000
5th and 6th anniversaries
Subsequent Event [Line Items]
Maintenance fee	25,000
7th anniversary and each year thereafter
Subsequent Event [Line Items]
Maintenance fee	$50,000

SUBSEQUENT_EVENTS_Detail_Textu

SUBSEQUENT EVENTS (Detail Textuals) (Subsequent Event, Northwestern University ("Northwestern"), License Agreement, USD $)	1 Months Ended
	Jan. 26, 2015	Nov. 18, 2014
Subsequent Event [Line Items]
Amount of funds raised within the first 12 months of the closing date	$3,000,000
Period for initiating good laboratory practices	18 months
Period for filing new drug application	4 years
Period for submitting new drug application	10 years
Non-creditable, non-refundable licensing fee	24,000
Percentage of shares issued of the total outstanding shares	2.00%
Milestone payments	25,000
Minimum royalty payments	200,000
Out of pocket patent expenses		25,000
Percentage of net sales of Licensed Products, condition one	5.00%
Percentage of net sales of Licensed Products, condition two	2.00%
Percentage of licensee's obligation reduced	0.25%
Royalty rate payable to third parties	1.00%
Percentage of minimum royalty rate	2.50%
Percentage of payments prior to filing new drug application	15.00%
Percentage of payments after filing new drug application	5.00%
Percentage of payments received from corporate partner	10.00%
Percentage of payments received from assignee	10.00%
Phase I
Subsequent Event [Line Items]
Period for first dosing of patient	5 years
Milestone payments	50,000
Phase II
Subsequent Event [Line Items]
Period for first dosing of patient	6 years
Milestone payments	100,000
Phase III
Subsequent Event [Line Items]
Period for first dosing of patient	8 years
Milestone payments	250,000
Regulatory Approval
Subsequent Event [Line Items]
Milestone payments	$1,500,000

SUBSEQUENT_EVENTS_Detail_Textu1

SUBSEQUENT EVENTS (Detail Textuals 1) (Subsequent Event, University Of Rochester, License Agreement, USD $)	0 Months Ended
	Apr. 16, 2015
Subsequent Event [Line Items]
Number of common stock issued as one-time, non-refundable, non-creditable license	32,310
Value of common stock issued as one-time, non-refundable, non-creditable license	$200,000
Non-refundable minimum annual maintenance fee	15,000
Minimum annual spending on drug development for waiving pre-clinical trial annual maintenance fee	200,000
Non-refundable minimum annual maintenance fee after onset of clinical trials	25,000
Percentage of royalty earned for first threshold in net revenue	5.00%
First threshold limit in net revenue	10,000,000
Percentage of royalty earned for second threshold in net revenue	4.00%
Second threshold limit in net revenue	10,000,000
Percentage of royalty earned for third threshold in net revenue	3.00%
Third threshold limit in net revenue	10,000,000
Percentage of royalty earned for fourth threshold in net revenue	2.00%
Fourth threshold limit in net revenue	10,000,000
Percentage of royalty earned for all remaining net revenue	1.00%
Percentage of cash and non-cash consideration derived from sublicenses	50.00%
Amount paid on before clinical trials initiation	300,000
Maximum number of days of initiation	30 days
Phase II
Subsequent Event [Line Items]
Amount paid on before clinical trials initiation	200,000
Maximum number of days of initiation	30 days
Phase III
Subsequent Event [Line Items]
Amount paid on before clinical trials initiation	200,000
Maximum number of days of initiation	30 days
Phase I, II and III
Subsequent Event [Line Items]
Amount paid on clinical trials sponsorship	$500,000
Maximum number of days of approval	30 days

SUBSEQUENT_EVENTS_Detail_Textu2

SUBSEQUENT EVENTS (Detail Textuals 2) (Subsequent Event, Asset Purchase Agreement, Faulk Pharmaceuticals, Inc. ("Faulk"), USD $)	0 Months Ended
	Apr. 06, 2015	Apr. 02, 2015
	Patent
Subsequent Event [Line Items]
Number of granted patents owned	23
Number shares approved for issuance to purchase assets	50,000	50,000
Number of expiration period of last patents conveyed	10 years
Percentage of royalty earned for first threshold in net revenue	5.00%
First threshold limit in net revenue	$10,000,000
Percentage of royalty earned for second threshold in net revenue	4.00%
Second threshold limit in net revenue	10,000,000
Percentage of royalty earned for third threshold in net revenue	3.00%
Third threshold limit in net revenue	10,000,000
Percentage of royalty earned for fourth threshold in net revenue	2.00%
Fourth threshold limit in net revenue	10,000,000
Percentage of fifth threshold in net revenue	1.00%
Fifth threshold limit in net revenue	$40,000,000
Shares beginning 6 months after the closing date
Subsequent Event [Line Items]
Percentage of shares assigned or transfer in open market after the closing date	33.00%
Shares beginning 9 months after the closing date
Subsequent Event [Line Items]
Percentage of shares assigned or transfer in open market after the closing date	33.00%
Shares beginning 12 months after the closing date
Subsequent Event [Line Items]
Percentage of shares assigned or transfer in open market after the closing date	34.00%

SUBSEQUENT_EVENTS_Detail_Textu3

SUBSEQUENT EVENTS (Detail Textuals 3) (Subsequent Event, Restricted common stock, USD $)	0 Months Ended
	Apr. 02, 2015	Feb. 04, 2015
Subsequent Event [Line Items]
Number of restricted common shares approved for issuance		1,345,000
Closing price per share at the date of grant	6.95	2.6
Restriction will be removed on February 4, 2016
Subsequent Event [Line Items]
Percentage of restricted shares earned	33.00%	33.00%
Restriction will be removed on February 4, 2017
Subsequent Event [Line Items]
Percentage of restricted shares earned	33.00%	33.00%
Restriction will be removed on February 4, 2018
Subsequent Event [Line Items]
Percentage of restricted shares earned	34.00%	34.00%

SUBSEQUENT_EVENTS_Detail_Textu4

SUBSEQUENT EVENTS (Detail Textuals 4) (Subsequent Event, USD $)	0 Months Ended
	Apr. 06, 2015	Apr. 02, 2015	Feb. 04, 2015
Subsequent Event [Line Items]
Number of directors and officers		2
Asset Purchase Agreement | Faulk Pharmaceuticals, Inc. ("Faulk")
Subsequent Event [Line Items]
Number shares approved for issuance to purchase assets	50,000	50,000
Restricted common stock
Subsequent Event [Line Items]
Number of restricted common shares approved for issuance		260,000
Closing price per share at the date of grant		6.95	2.6
Restricted common stock | Restriction will be removed on April 2, 2016
Subsequent Event [Line Items]
Percentage of restricted shares earned		33.00%	33.00%
Restricted common stock | Restriction will be removed on April 2, 2017
Subsequent Event [Line Items]
Percentage of restricted shares earned		33.00%	33.00%
Restricted common stock | Restriction will be removed on April 2, 2018
Subsequent Event [Line Items]
Percentage of restricted shares earned		34.00%	34.00%